These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 6221010)

  • 41. [In vitro activity of seven gyrase inhibitors of a group of heterocyclic carbonic acids against nonfermenting gram negative rods (nonfermenters)].
    Grimm H
    Arzneimittelforschung; 1985; 35(3):570-2. PubMed ID: 2986655
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro activities of ciprofloxacin, norfloxacin, pipemidic acid, cinoxacin, and nalidixic acid against Chlamydia trachomatis.
    Heessen FW; Muytjens HL
    Antimicrob Agents Chemother; 1984 Jan; 25(1):123-4. PubMed ID: 6230988
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Norfloxacin sensitivity of bacterial pathogens of urinary tract infections].
    Modde H
    Schweiz Rundsch Med Prax; 1985 Apr; 74(17):439-42. PubMed ID: 3159064
    [No Abstract]   [Full Text] [Related]  

  • 44. Experiences on the efficacy and safety of nalidixic acid, oxolinic acid, cinoxacin and norfloxacin in the treatment of urinary tract infections (UTI).
    Sabbour MS; El Bokl MA; Osman LM
    Infection; 1984; 12(6):377-80. PubMed ID: 6240470
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of acute urinary infection by norfloxacin or nalidixic acid/citrate: a multi-centre comparative study.
    Reeves DS; Lacey RW; Mummery RV; Mahendra M; Bint AJ; Newsom SW
    J Antimicrob Chemother; 1984 May; 13 Suppl B():99-105. PubMed ID: 6234282
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Norfloxacin in acute urinary tract infections.
    Deaney NB; Vogel R; Vandenburg MJ; Currie WJ
    Practitioner; 1984 Jan; 228(1387):111-7. PubMed ID: 6229726
    [No Abstract]   [Full Text] [Related]  

  • 47. [Prevalence of susceptibility to quinolones and other antibiotics in microorganisms isolated from community bacteriuria in Madrid in 1995. Study Group of Infections in Primary Care].
    Alós Cortés JI; Balas Fuertes D; Gómez Garcés JL
    Rev Clin Esp; 1997 Mar; 197(3):167-71. PubMed ID: 9273581
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antibiotic sensitivity and resistance profile of the micro-organisms responsible for urinary tract infection observed in Kashmir, India.
    Kadri SM; Gash B; Rukhsana A
    J Indian Med Assoc; 2002 Nov; 100(11):656, 658-60. PubMed ID: 12797637
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The in-vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid.
    King A; Shannon K; Phillips I
    J Antimicrob Chemother; 1984 Apr; 13(4):325-31. PubMed ID: 6233249
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Nitrofurans: a modern treatment for uncomplicated urinary infections?].
    Cahen P; Honderlick P
    Pathol Biol (Paris); 2000 Jun; 48(5):470-1. PubMed ID: 10949843
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative in vitro studies with 4-quinolone antimicrobials.
    Felmingham D; O'Hare MD; Robbins MJ; Wall RA; Williams AH; Cremer AW; Ridgway GL; Grüneberg RN
    Drugs Exp Clin Res; 1985; 11(5):317-29. PubMed ID: 2941259
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bacteriology of urinary tract infections and the effectiveness of antimicrobials against the urinary pathogens.
    Sengupta SR; Bansal MP; Deshpande PK; Sharma KD
    J Assoc Physicians India; 1972 Oct; 20(10):755-9. PubMed ID: 4570011
    [No Abstract]   [Full Text] [Related]  

  • 53. The assessment of antimicrobial activity in an in-vitro model of the treatment of bacterial cystitis.
    Greenwood D
    J Antimicrob Chemother; 1984 May; 13 Suppl B():43-8. PubMed ID: 6234274
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The in vitro and in vivo activity of ciprofloxacin.
    Zeiler HJ; Grohe K
    Eur J Clin Microbiol; 1984 Aug; 3(4):339-43. PubMed ID: 6237902
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro antibacterial activity of norfloxacin and other agents against ocular pathogens.
    Shungu DL; Tutlane VK; Weinberg E; Gadebusch HH
    Chemotherapy; 1985; 31(2):112-8. PubMed ID: 3157551
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vitro antibacterial activity of norfloxacin (MK-0366, AM-715) and other agents against gastrointestinal tract pathogens.
    Shungu DL; Weinberg E; Gadebusch HH
    Antimicrob Agents Chemother; 1983 Jan; 23(1):86-90. PubMed ID: 6219622
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The treatment of Pseudomonas aeruginosa urinary tract infections with norfloxacin.
    Leigh DA; Emmanuel FX
    J Antimicrob Chemother; 1984 May; 13 Suppl B():85-8. PubMed ID: 6234280
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Comparative bacteriologic activity of norfloxacin, ofloxacin and pefloxacin against 320 Gram-negative bacilli resistant and non-resistant to nalidixic acid and cephalosporins].
    Croize J; Le Noc P; Bryskier A; Robert J
    Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):564-8. PubMed ID: 3937128
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Structure-activity relationships in the quinolone group: antibacterial activity of two new compounds (author's transl)].
    Thibault M; Koumaré B; Soussy CJ; Duval J
    Ann Microbiol (Paris); 1981; 132(3):267-81. PubMed ID: 6457546
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of gram-negative rods and staphylococci isolated from infected hospitalised patients.
    Guimaraes MA; Noone P
    J Antimicrob Chemother; 1986 Jan; 17(1):63-7. PubMed ID: 2936708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.